Plain-English translation of NCT05895838 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a common anti-inflammatory medication, to see if it can help improve survival and brain recovery in people who have survived cardiac arrest outside of a hospital. After cardiac arrest, the body experiences severe inflammation and brain injury even after the heart is restarted. This study will compare given intravenously over three doses with a placebo to see if the medication reduces complications and improves outcomes.
Even with the best current care, about half of people hospitalized after surviving cardiac arrest do not make it. Most deaths happen because of irreversible brain damage. This trial exists to test whether reducing inflammation early on can protect the brain and help more people recover.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive either the anti-inflammatory medication or a placebo as three intravenous infusions given over 15 minutes each — the first as soon as possible after hospital admission, and then two more daily infusions. You will stay in the hospital as part of standard cardiac arrest care, where doctors will monitor your heart, breathing, and brain function closely over several days. Researchers will follow your recovery and outcomes for up to 6 months after your cardiac arrest.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
Denmark